These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 18482433)

  • 21. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats.
    Shoaib M
    Neuropharmacology; 2008 Feb; 54(2):438-44. PubMed ID: 18054052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rimonabant--a selective CB1 antagonist.
    Boyd ST; Fremming BA
    Ann Pharmacother; 2005 Apr; 39(4):684-90. PubMed ID: 15755787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats.
    Cohen C; Perrault G; Voltz C; Steinberg R; Soubrié P
    Behav Pharmacol; 2002 Sep; 13(5-6):451-63. PubMed ID: 12394421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Blocking cannabinoid receptors. Simultaneous control of overweight and nicotine addiction].
    MMW Fortschr Med; 2004 Mar; 146(10):44. PubMed ID: 15347084
    [No Abstract]   [Full Text] [Related]  

  • 25. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
    Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
    Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
    McMahon LR; Koek W
    Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.
    Colombo G; Orrù A; Lai P; Cabras C; Maccioni P; Rubio M; Gessa GL; Carai MA
    Mol Neurobiol; 2007 Aug; 36(1):102-12. PubMed ID: 17952655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist Rimonabant (SR141716A).
    Diergaarde L; de Vries W; Raasø H; Schoffelmeer AN; De Vries TJ
    Neuropharmacology; 2008 Oct; 55(5):712-6. PubMed ID: 18588903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence.
    Le Foll B; Goldberg SR
    J Pharmacol Exp Ther; 2005 Mar; 312(3):875-83. PubMed ID: 15525797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys.
    Justinová Z; Yasar S; Redhi GH; Goldberg SR
    J Neurosci; 2011 May; 31(19):7043-8. PubMed ID: 21562266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug addiction.
    Justinova Z; Panlilio LV; Goldberg SR
    Curr Top Behav Neurosci; 2009; 1():309-46. PubMed ID: 21104390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The psychiatric side-effects of rimonabant.
    Moreira FA; Crippa JA
    Braz J Psychiatry; 2009 Jun; 31(2):145-53. PubMed ID: 19578688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
    Gelfand EV; Cannon CP
    J Am Coll Cardiol; 2006 May; 47(10):1919-26. PubMed ID: 16697306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attenuation of cue-induced reinstatement of nicotine seeking by URB597 through cannabinoid CB1 receptor in rats.
    Forget B; Guranda M; Gamaleddin I; Goldberg SR; Le Foll B
    Psychopharmacology (Berl); 2016 May; 233(10):1823-8. PubMed ID: 26864774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabinoid CB1 receptor antagonist rimonabant disrupts nicotine reward-associated memory in rats.
    Fang Q; Li FQ; Li YQ; Xue YX; He YY; Liu JF; Lu L; Wang JS
    Pharmacol Biochem Behav; 2011 Oct; 99(4):738-42. PubMed ID: 21722663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats.
    Rubio M; Fernández-Ruiz J; de Miguel R; Maestro B; Michael Walker J; Ramos JA
    Neuropharmacology; 2008 May; 54(6):976-88. PubMed ID: 18371990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents.
    Griebel G; Stemmelin J; Scatton B
    Biol Psychiatry; 2005 Feb; 57(3):261-7. PubMed ID: 15691527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM; Wakley AA; Tsutsui KT; Laggart JD
    J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.